$PFGC

Performance Food Group Co (PFGC): Results of Operations and Financial Condition

Performance Food Group Co (PFGC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 pfgc-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 NEWS RELEASE For Immediate Release Investors: Media: William S. Marshall Scott Golden SVP, Investor Relations Director, Communications & Engagement (804) 287-8108 (804) 484-7873 Bill.Marshall@pfgc.com Scott.Golden@pfgc.com Pe

Original reporting
Published Aug 12, 2026, 11:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 11:10 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$PFGC
Bullish
medium confidence
Mentioned
$PFGC
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PFGCBullishHigh
01

Why it matters

Traders can update valuation and positioning based on the reported operating momentum (case volume, net sales, gross profit, cash flow) and the company’s stated 2027 outlook.

02

Market read

The filing combines a full earnings-style datapack with forward guidance, making it a direct input to near-term expectation setting.

03

What to watch

Operating expenses rose notably, including fuel, personnel, depreciation from finance leases, and legal/professional costs tied to shareholder activism and US Foods clean team agreement, which could pressure future margins if these costs persist.

Relevance 7/10Novelty 8/10Timing: pre-market today (8-K filed Aug 12, 2026)

Background

This is an SEC Form 8-K with an attached earnings release (Exhibit 99.1) covering Q4 and full-year fiscal 2026 results and announcing full-year fiscal 2027 guidance.

Company-level read

Ticker impact

$PFGCBullishMedium confidence
Context

Performance Food Group reported Q4 and full-year fiscal 2026 results and announced full-year 2027 financial guidance in its 8-K.

Expected impact

Likely positive bias for the stock as guidance and cash-flow metrics improved, though the magnitude depends on how 2027 guidance compares to Street expectations.

Evidence & confidence

The release cites broad volume growth, higher net sales, improved gross profit, and operating cash flow and free cash flow, alongside a stated 2027 outlook. The excerpt includes the guidance announcement but truncates the detailed guidance numbers, limiting precision on upside/downside.

Market effects

Independent foodservice distribution demand signals and margin/cost dynamics (fuel, inflation, rebates) can influence sentiment across broadline distributors and related logistics inputs.

Limited direct regional read-through; Richmond-based issuer with national distribution footprint.

Low direct global linkage; primarily US foodservice distribution and cost inflation.

Counterpoint

Volume growth may be partially mix and pricing driven (inflation and selling price per case), so margin durability could be questioned if cost inflation reverses.

Key entities

  • Performance Food Group Company

    NYSE-listed distributor reporting fiscal 2026 results and providing full-year 2027 financial guidance.

  • Cheney Bros., Inc.

    Referenced acquisition contributing to net sales growth and operating expense changes.

  • US Foods Holding Corp.

    Referenced in connection with a clean team agreement and related legal/professional costs.

Related articles

$PFGCMed

Why is Performance Food Group stock sliding today?

Performance Food Group (PFGC) shares fell about 4.5% in pre-open trading after the company reported fiscal Q4 2026 results. Earnings were $1.59 per share, slightly below the $1.60 consensus, and revenue was $18.0 billion versus $18.07 billion expected, according to Investing.com. The article also cites prior estimate declines and CEO George L. Holm selling shares.

$APREMed

Aprea Therapeutics, Inc. (APRE): Results of Operations and Financial Condition

Aprea Therapeutics, Inc. (APRE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 apre-20260812xex99d1.htm EX-99.1 ​ Exhibit 99.1 ​ Aprea Therapeutics Announces Second Quarter 2026 Financial Results ​ Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances Aprea p